Author: Cui, Ran; Zhu, Ying; Wang, Yulan; Chen, Xiao-Hua; Li, Qiang; Dai, Sheng-Ming; Tong, Qiang
Title: Tocilizumab in the treatment of coronavirus disease 2019 pneumonia: real-world data from a case series Cord-id: lymclrme Document date: 2021_5_24
ID: lymclrme
Snippet: Aim: Coronavirus disease 2019 is a life-threatening disease and how to improve survival of the patients is of great importance. Objective: To determine whether tocilizumab (TCZ) shows favorable results in coronavirus disease 2019 patients. Materials & methods: A retrospective study of four patients who received TCZ was conducted from 19 February to 31 March 2020 at Leishenshan Hospital, Wuhan, China. Clinical data of patients were compared before and after the administration of the agent. Result
Document: Aim: Coronavirus disease 2019 is a life-threatening disease and how to improve survival of the patients is of great importance. Objective: To determine whether tocilizumab (TCZ) shows favorable results in coronavirus disease 2019 patients. Materials & methods: A retrospective study of four patients who received TCZ was conducted from 19 February to 31 March 2020 at Leishenshan Hospital, Wuhan, China. Clinical data of patients were compared before and after the administration of the agent. Results: There was not much difference in the clinical feature improvements and computed tomography images after TCZ administration in two mild patients. The other two severe patients died of disseminated intravascular coagulation and acute respiratory distress syndrome, respectively. Conclusion: Administration of TCZ was not shown a favorable outcome in this preliminary uncontrolled case series.
Search related documents:
Co phrase search for related documents- ace inhibitor and lung disease: 1
- ace inhibitor and lung function: 1, 2
- ace inhibitor and lymphocyte count: 1
- acute respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory distress syndrome and lung epithelial cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute respiratory distress syndrome and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory distress syndrome and lymphocyte decrease count: 1
- admission detectable and lung damage: 1
- admission detectable and lung disease: 1, 2
- admission negative and lung damage: 1
- admission negative and lung disease: 1, 2
- admission negative and lung function: 1
- admission negative and lymphocyte count: 1, 2, 3
- admission severe type and lymphocyte count: 1, 2
- long duration and lung damage: 1, 2
- long duration and lung disease: 1
- long duration and lung function: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date